BeiGene, Ltd. - Asset Resilience Ratio
BeiGene, Ltd. (ONC) has an Asset Resilience Ratio of 0.00% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore BeiGene, Ltd. total assets for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2023)
This chart shows how BeiGene, Ltd.'s Asset Resilience Ratio has changed over time. See net asset quality index of BeiGene, Ltd. to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down BeiGene, Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of BeiGene, Ltd..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: BeiGene, Ltd. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
BeiGene, Ltd. Industry Peers by Asset Resilience Ratio
Compare BeiGene, Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for BeiGene, Ltd. (2014–2023)
The table below shows the annual Asset Resilience Ratio data for BeiGene, Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.04% | $2.60 Million | $5.81 Billion | -10.38pp |
| 2022-12-31 | 10.43% | $665.25 Million | $6.38 Billion | -15.84pp |
| 2021-12-31 | 26.27% | $2.24 Billion | $8.54 Billion | -32.10pp |
| 2020-12-31 | 58.36% | $3.27 Billion | $5.60 Billion | +35.74pp |
| 2019-12-31 | 22.62% | $364.73 Million | $1.61 Billion | -24.87pp |
| 2018-12-31 | 47.50% | $1.07 Billion | $2.25 Billion | -9.64pp |
| 2017-12-31 | 57.14% | $597.91 Million | $1.05 Billion | -12.02pp |
| 2016-12-31 | 69.16% | $280.66 Million | $405.81 Million | -1.60pp |
| 2015-12-31 | 70.76% | $82.62 Million | $116.76 Million | +13.88pp |
| 2014-12-31 | 56.88% | $30.50 Million | $53.62 Million | -- |
About BeiGene, Ltd.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatm… Read more